Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New Data on Immune Checkpoint Inhibitor–Associated ITP (ICI-ITP)
A large multi-center analysis across 86,000+ patients reveals that ICI-ITP—though rare—is a clinically significant and high-risk complication of immunotherapy.
Key Findings:
- Incidence: 1 in 400 patients
- 30% recurrence rate with ICI rechallenge
- 75% recover, but severity of ICI-ITP is independently linked to higher mortality
- Severe cases carry a ~3-fold increased risk of death (adjusted HR 2.96)
Risk factors:
- Lower baseline platelets
- Combination ICI therapy
- Stage IV disease
- Additional irAEs
Median onset: 8 weeks after starting ICI
Median nadir platelets: 41 × 10⁹/L
Treatments used: steroids, IVIG, and TPO-RA.
Why this matters:
This is the largest and most comprehensive study to date, defining the incidence, risk factors, clinical course, and survival impact of ICI-ITP. Early recognition and aggressive management are essential.”
Title: Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Authors: Rebecca Karp Leaf, Jodi V. Mones, Tushar Shenoy, Mohamed Warsame, Marina Beltrami-Moreira, Sandhya Panch, Andrew D. Leavitt, Rebecca L. Zon, Ellen K Kendall, Sahar Shahamatdar, Tristan Lee Lim, Can Cui, Debbie Jiang, Sarah A. Kaunfer, Lavanya Durai, Steven T. Hoge, Julie-Alexia Dias, Carrie Sha, Aaron Holmes, Neela Easton, Elizabeth Corley, Ethan Zhao, Xingyi Li, Amy Spelman, Christina Briggs Amos, Doris R Soebbing, Maria Shabih, Trevor Jamison, Bolun Liu, Guleid Hussein, Sumeet Kumar Yadav, Mohamed I. Elsaid, Dwight H. Owen, Alexa Mera, Patrick K. Juras, Arvind Suresh, Marina J. Heskel, Jennifer J. Huang, Ilya Glezerman, Ronald S. Go, Kerry Reynolds, Hanny Al-Samkari, Michael H. Kroll, David E. Leaf
You can read the full article in ASH Blood.
More posts featuring Yan Leyfman.